Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT07230353 Sponsor: Xencor, Inc. Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT07230353
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been diagnosed with rheumatoid arthritis (RA) that is moderately to severely active
  • People who received a confirmed RA diagnosis at least 3 months before the screening visit, meeting recognised classification standards for RA
  • People whose current RA treatments have not worked well enough, have stopped working, or have caused side effects they could not tolerate
  • People who have been on stable doses of their RA medications for a set period before the screening visit
  • People who are using highly effective methods of contraception

Who may not be able to join:

  • People who have had major surgery within the 12 weeks before screening, or who have major surgery planned within 12 months after receiving the trial treatment
  • People who have frequent infections or a current significant active infection
  • People who have active tuberculosis (TB) or latent TB that has not been treated
  • People who have been diagnosed with cancer, have a history of cancer, or have had a disease involving abnormal growth of lymph cells within the past 5 years
  • People who have an uncontrolled condition affecting the heart, lungs, kidneys, liver, hormonal system, or digestive system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Xencor, Inc.
Registry
ClinicalTrials.gov
Start date
21 October 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇬🇪 Georgia Moldova 🇳🇿 New Zealand

Primary endpoints

Primary

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov